Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7136213 | 1.00 | DRD2 (0.45) | DRD2HSD11B1OPRM1NR1H3NR1H2 | |
| SCHEMBL7132219 | 0.90 | HSD11B1 (0.46) | DRD2HSD11B1OPRM1NR1H2 | |
| SCHEMBL7132216 | 0.90 | HSD11B1 (0.46) | DRD2HSD11B1OPRM1NR1H2 | |
| SCHEMBL7134138 | 0.85 | DRD2 (0.62) | DRD2OPRM1NR1H3NR1H2DRD3 | |
| SCHEMBL7134135 | 0.85 | DRD2 (0.62) | DRD2OPRM1NR1H3NR1H2DRD3 | |
| SCHEMBL7134126 | 0.85 | HSD11B1 (0.40) | HSD11B1OPRM1NR1H2 | |
| SCHEMBL7134133 | 0.85 | HSD11B1 (0.40) | HSD11B1OPRM1NR1H2 | |
| SCHEMBL3453542 | 0.79 | DRD2 (0.72) | DRD2DRD3 | |
| SCHEMBL7132786 | 0.79 | ALDH1A1 (0.55) | DRD2OPRM1 | |
| SCHEMBL7132782 | 0.79 | ALDH1A1 (0.55) | DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240141-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030109532-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109532-A1 | Modulators of dopamine neurotransmission | OPRD1, CHRNA5, OPRM1 | DRD2 12/4885HSD11B1 2821/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.